JP2020530499A5 - - Google Patents

Download PDF

Info

Publication number
JP2020530499A5
JP2020530499A5 JP2020530715A JP2020530715A JP2020530499A5 JP 2020530499 A5 JP2020530499 A5 JP 2020530499A5 JP 2020530715 A JP2020530715 A JP 2020530715A JP 2020530715 A JP2020530715 A JP 2020530715A JP 2020530499 A5 JP2020530499 A5 JP 2020530499A5
Authority
JP
Japan
Prior art keywords
influenza
virus
cannabidiol
subtype
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020530715A
Other languages
English (en)
Japanese (ja)
Other versions
JP6963719B2 (ja
JP2020530499A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2017/099956 external-priority patent/WO2019041239A1/zh
Publication of JP2020530499A publication Critical patent/JP2020530499A/ja
Publication of JP2020530499A5 publication Critical patent/JP2020530499A5/ja
Application granted granted Critical
Publication of JP6963719B2 publication Critical patent/JP6963719B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020530715A 2017-08-31 2017-08-31 抗インフルエンザ薬の調製におけるカンナビジオールの用途 Expired - Fee Related JP6963719B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/099956 WO2019041239A1 (zh) 2017-08-31 2017-08-31 大麻二酚在制备抗流感的药物中的用途

Publications (3)

Publication Number Publication Date
JP2020530499A JP2020530499A (ja) 2020-10-22
JP2020530499A5 true JP2020530499A5 (enExample) 2020-12-03
JP6963719B2 JP6963719B2 (ja) 2021-11-10

Family

ID=65524611

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020530715A Expired - Fee Related JP6963719B2 (ja) 2017-08-31 2017-08-31 抗インフルエンザ薬の調製におけるカンナビジオールの用途

Country Status (6)

Country Link
US (1) US11452707B2 (enExample)
EP (1) EP3677258B1 (enExample)
JP (1) JP6963719B2 (enExample)
AU (1) AU2017429312B2 (enExample)
CA (1) CA3073576C (enExample)
WO (1) WO2019041239A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113116867B (zh) * 2019-12-31 2022-08-23 汉义生物科技(北京)有限公司 一种预防和/或治疗流感的组合物
CN111249266B (zh) * 2020-03-06 2022-08-09 中国人民解放军海军军医大学 帕拉米韦在制备治疗感染性疾病引起炎症风暴的药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011005411A (es) * 2008-11-25 2011-06-16 Alder Biopharmaceuticals Inc Anticuerpos de il-6 y uso de los mismos.
FR2953410B1 (fr) * 2009-12-09 2012-02-24 Univ Claude Bernard Lyon Compositions antivirales pharmaceutiques ou veterinaires
US20130203715A1 (en) * 2010-07-20 2013-08-08 Pulmatrix, Inc. Use of trp channel agonists to treat infections
US9308213B2 (en) * 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
GB201018289D0 (en) * 2010-10-29 2010-12-15 Biocopea Ltd Treatment of respiratory disorders
RU2635188C2 (ru) * 2011-02-04 2017-11-09 ИнФёрст Хэлткэр Лимитед Композиции и способы для лечения хронического воспаления и воспалительных заболеваний
WO2016092539A1 (en) * 2014-12-07 2016-06-16 One World Cannabis Ltd Use of cannabis to treat migraine
US20160317468A1 (en) * 2015-04-28 2016-11-03 Raman Sankar Uses of cannabidiol for treatment of infantile spasms
US20180116998A1 (en) * 2015-05-13 2018-05-03 One World Cannabis Ltd Use of cannabis to treat fibromyalgia, methods and compositions thereof
JP7454332B2 (ja) * 2016-06-15 2024-03-22 オーハイ エナジェティクス ピービーシー 酸化ストレスを低減するための方法および組成物

Similar Documents

Publication Publication Date Title
Khomich et al. Redox biology of respiratory viral infections
Govorkova et al. Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002–2012 shows need for continued monitoring
Hsieh et al. Strategies of development of antiviral agents directed against influenza virus replication
Yen et al. Pandemic influenza as a current threat
Li et al. Enhancement of influenza virus transmission by gene reassortment
Saha et al. Glucosyl hesperidin prevents influenza a virus replication in vitro by inhibition of viral sialidase
Wang et al. Novel pandemic influenza A (H1N1) virus infection modulates apoptotic pathways that impact its replication in A549 cells
Shinya et al. Toll-like receptor pre-stimulation protects mice against lethal infection with highly pathogenic influenza viruses
WO2011143262A3 (en) Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
Govorkova et al. Therapeutics against influenza
Hoffmann et al. A new class of synthetic anti-lipopolysaccharide peptides inhibits influenza A virus replication by blocking cellular attachment
Lu et al. Peptidomimetic furin inhibitor MI-701 in combination with oseltamivir and ribavirin efficiently blocks propagation of highly pathogenic avian influenza viruses and delays high level oseltamivir resistance in MDCK cells
Gong et al. Potential targets and their relevant inhibitors in anti-influenza fields
Eyer et al. Antiviral agents targeting the influenza virus: a review and publication analysis
Zhang et al. p-STAT1 regulates the influenza A virus replication and inflammatory response in vitro and vivo
Ludwig et al. Influenza, a One Health paradigm—novel therapeutic strategies to fight a zoonotic pathogen with pandemic potential
Su et al. Global and quantitative proteomic analysis of dogs infected by avian-like H3N2 canine influenza virus
Ilyushina et al. In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate
Cinatl Jr et al. The threat of avian influenza A (H5N1). Part III: antiviral therapy
Davis et al. Emerging antiviral resistant strains of influenza A and the potential therapeutic targets within the viral ribonucleoprotein (vRNP) complex
Yang et al. Design, synthesis and biological evaluation of small molecular polyphenols as entry inhibitors against H5N1
RU2568849C1 (ru) Средство, представляющее собой амид глицирризиновой кислоты с 5-аминоурацилом, проявляющее противовирусную активность в отношении вируса гриппа a/h1n1
Zhang et al. Identification of novel virus inhibitors by influenza A virus specific reporter cell based screening
RU2580305C1 (ru) ПРОТИВОВИРУСНОЕ СРЕДСТВО НА ОСНОВЕ СУХОГО ЭКСТРАКТА ЛИШАЙНИКА Cetraria islandica
Wu et al. Transcriptome profiling reveals a peculiarity of host immune responses to PA-X protein of H9N2 influenza A virus